Grants for Public Housing Authorities

This grant provides funding for innovative researchers focused on addressing and reducing substance use-related health disparities among underserved racial and ethnic minority populations in the U.S.

This grant provides funding for researchers to investigate the genetic and environmental causes of structural birth defects, promoting collaboration between scientists and clinicians to improve prevention and treatment strategies.

This funding opportunity supports research that explores how structural racism affects brain function and substance use risk, aiming to develop effective prevention strategies for substance use disorders among racial and ethnic minority populations.

This funding opportunity provides early-career clinical scientists with financial support and mentorship to develop their research skills in improving healthcare delivery, quality, and access in the United States.

This grant provides funding for collaborative research teams to develop and test strategies that address and reduce racial and ethnic disparities in substance use and addiction, prioritizing community-driven issues.

This grant provides funding for researchers to explore how Mycobacterium tuberculosis and HIV affect host cell death pathways, with the goal of developing new therapies to improve treatment outcomes for co-infected individuals.

This funding opportunity supports research centers focused on understanding how biological sex differences affect women's health, promoting interdisciplinary collaboration and workforce diversity in the scientific community.

This funding opportunity supports researchers exploring the biological mechanisms of bladder cancer to improve understanding and treatment of this prevalent disease.

This grant provides funding to early-career researchers in mental health to support innovative projects that advance the understanding and treatment of mental illnesses.

This funding opportunity supports research into the biology and mechanisms of bladder cancer, encouraging multidisciplinary teams to explore both normal bladder functions and cancer processes using clinical specimens.

This funding opportunity provides long-term financial support to experienced cancer researchers who are pursuing innovative and high-risk projects that could lead to significant advancements in cancer science.

This grant provides funding for innovative early-stage cancer research projects that could lead to significant advancements in diagnosis, treatment, and prevention, targeting a wide range of eligible organizations including universities, nonprofits, and small businesses.

This funding opportunity supports early-career clinical researchers in the U.S. to develop expertise in implementation science for substance use prevention and treatment through mentored clinical trials addressing the overdose crisis.

This funding opportunity supports early-career researchers in the U.S. to develop their skills in implementation science for effective substance use prevention and treatment, enabling them to lead clinical trials that address the opioid crisis.

This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.

This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

This grant provides funding to improve safety training programs for commercial fishermen in the United States, ensuring they receive effective education to reduce workplace injuries and enhance safety practices.

This grant provides funding for large-scale, collaborative research projects that explore complex questions related to aging, requiring a multidisciplinary team and integration of various components across institutions.

The "CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development" grant aims to fund the early-stage development of treatments to reduce the harmful health effects caused by exposure to toxic chemicals, which could be used in terrorist attacks or accidentally released from industrial sites, with the end goal of producing at least one well-characterized therapeutic candidate.

The "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required" grant aims to fund clinical trials that test the effectiveness and safety of new treatments for rare diseases, with the goal of increasing the number of approved treatments for these conditions.